Kyowa Hakko Kirin Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kyowa Hakko Kirin Co. Ltd.
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.
National Advertising Division sides with RxBar marketer in review of front-of-package list of ingredients and “No B.S.” statement challenged by Kind bars. NAD attorneys note food products commonly tout ingredients on labels without specifying relative prominence by weight, volume or other measures.
Warning letter and multiple form 483s fail to convince Custompax; Kellogg acquires RXBAR clean-label protein bars for $600m; NutraFuels used Blast Cap for products; and more news in brief.
Supplement firms' reports of serious adverse events jump since becoming mandatory in 2008 and FDA warnings on failures to report have been on the rise as companies labor to keep up with investigations and reporting duties. Similar challenges could lie ahead for cosmetics firms under House and Senate bills.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents